Emilie Finch
emiliefinch.bsky.social
Emilie Finch
@emiliefinch.bsky.social
Postdoc @Cambridge_Uni doing infectious disease modelling | Interested in arboviral dynamics, immunity, climate & forecasting | Previously @LSHTM
Great to collaborate with @chantalvogels.bsky.social, Afeez Sodeinde and their team on this comprehensive work looking at dengue virus & Wolbachia interactions, making the case for considering DENV genetic diversity when implementing Wolbachia-based control interventions - key findings below! 🦠🦟
September 26, 2025 at 10:13 AM
Reposted by Emilie Finch
No one best way to measure #infection risk in populations.

Cross-sectional sero: weak temporal signal, CXR, waning as we know. Extra care needed for longitudinal #serology as Ab kinetics and assay noise can mess up estimates by a lot. Cases can be powerful!
www.pnas.org/doi/10.1073/pnas.2411768121
Reconciling heterogeneous dengue virus infection risk estimates from different study designs | PNAS
Uncovering rates at which susceptible individuals become infected with a pathogen, i.e., the force of infection (FOI), is essential for assessing t...
eur03.safelinks.protection.outlook.com
January 1, 2025 at 3:19 AM
Reposted by Emilie Finch
1/ 🎉 Thrilled to share our new study: Quantifying the impact of pre-vaccination titre and vaccination history on influenza vaccine immunogenicity 🦠💉 Published in Vaccine! link: authors.elsevier.com/a/1kD7x,60n7... with @adamjkucharski.bsky.social
authors.elsevier.com
December 5, 2024 at 7:59 AM
A great opportunity to work with an incredible team! You may even get to label some cryotubes (as pictured below)
Come do a PhD with us at @lshtm.bsky.social! We're advertising two projects:

Understanding and predicting vector-borne epidemics (with Rachel Lowe): mrc-lid.lshtm.ac.uk/2025-26-proj...

Kinetics of immunity to influenza and SARS-CoV-2 (with @dchodge.bsky.social): mrc-lid.lshtm.ac.uk/2025-26-proj...
November 22, 2024 at 4:01 PM